To offer you a better experience, our website uses some cookies. To continue the visit, please accept our cookie policy

I agree

Cookies information

Our site uses tools, such as cookies, to analyze and improve your experience. You can unsubscribe below:


We use tools, such as Google Analytics, to track web traffic and verify the effectiveness of our site.


Cookies required for essential services and features such as login forms, shopping cart integration and access control. Without them, our website cannot function properly and we cannot provide any services. Deactivation is not available.

These settings will be kept for 24h

  • Bioxodes

    is a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics to prevent thrombotic events without hemorrhagic risk.

    Read more
  • Ir-CPI

    Our lead candidate with unique mechanism of action against thrombo-inflammatory diseases

    Read more



Bioxodes takes advantage of its deep understanding of the thrombotic process to design drug candidates with an aim to achieve anticoagulation without hemorrhagic risk.

Our lead drug candidate, Ir-CPI, targets coagulation factors XIIa and XIa and prevents Neutrophil Extracellular Trap (NET) release, key driver components of the thrombo-inflammatory process.

In parallel, Bioxodes is developing a pipeline of drug candidates targeting chronic inflammatory diseases.

Visit About us

Our innovative pipeline includes a clinical-stage program with Ir-CPI for the prevention of acute thrombo-inflammatory processes. The initiation of the Phase IIa program to collect first evidence of efficacy in patients is expected early 2022.



All products

Scientific & Clinical Advisory Board

All Key opinion leaders

Recents News


Invest in us

Why invest

Bioxodes is a Belgian private company, founded in 2013. The Company has received fundings from both the public and private investors.

  • Sfpi - Fpim
  • Financière spin-off Luxembourgeoise
  • Sambrinvest
  • LSRP - Life Sciences Research Partners
  • Business angels
All investors